Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
- S&P DJI Announces March 2021 Quarterly Rebalance
- Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
- Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
- Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
Later from Imugene
- Imugene announces clinical milestone for HER-Vaxx
- Appendix 4C - quarterly
- Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
- Investor Presentation
- FDA IND approval of new oncolytic virotherapy CHECKvacc
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene